Autopsy report · NCT00707655

Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy

Cause of deathFunding or business Automatic label, confidence 0.5, unverified. How labels are made.

“The decision is based on company re-evaluation of indications to be pursued within SCCHN”

The sponsor’s own words in the registry.

Life of this trial

Registered 3 months before it started.
Ran for about 2 years 1 month before it stopped.
8 participants enrolled.
Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 1, Phase 2
Sponsor: Genmab
Sponsor type: Industry
Conditions: Head and Neck Cancer; Squamous Cell Carcinoma
Interventions: Zalutumumab
Participants: 8
Sites: 8
Countries: Belgium, France, United Kingdom

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.